251 related articles for article (PubMed ID: 11296968)
21. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?
Schatz D; Cuthbertson D; Atkinson M; Salzler MC; Winter W; Muir A; Silverstein J; Cook R; Maclaren N; She JX; Greenbaum C; Krischer J
Pediatr Diabetes; 2004 Jun; 5(2):72-9. PubMed ID: 15189492
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of lipodystrophy in Thai-HIV infected patients.
Puttawong S; Prasithsirikul W; Vadcharavivad S
J Med Assoc Thai; 2004 Jun; 87(6):605-11. PubMed ID: 15279336
[TBL] [Abstract][Full Text] [Related]
23. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
24. Oral glucose tolerance test in children and adolescents: positives and pitfalls.
Conwell LS; Batch JA
J Paediatr Child Health; 2004 Nov; 40(11):620-6. PubMed ID: 15469531
[TBL] [Abstract][Full Text] [Related]
25. Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome.
Fardet L; Cabane J; Kettaneh A; Lebbé C; Flahault A
Rheumatology (Oxford); 2007 Jul; 46(7):1102-6. PubMed ID: 17409127
[TBL] [Abstract][Full Text] [Related]
26. Metabolic characteristics of subjects with normal glucose tolerance and 1-h hyperglycaemia.
Qian L; Fu X; Xu L; Zheng S; Zhou W; Wang X; Gu Y; Lin F; Luo M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):575-9. PubMed ID: 18248638
[TBL] [Abstract][Full Text] [Related]
27. Metabolic consequences of pancreatic systemic or portal venous drainage in simultaneous pancreas-kidney transplant recipients.
Petruzzo P; Badet L; Lefrançois N; Berthillot C; Dorel SB; Martin X; Laville M
Diabet Med; 2006 Jun; 23(6):654-9. PubMed ID: 16759308
[TBL] [Abstract][Full Text] [Related]
28. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
29. The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects.
Sabuncu T; Ucar E; Birden F; Yasar O
Diabetes Nutr Metab; 2004 Apr; 17(2):103-7. PubMed ID: 15244102
[TBL] [Abstract][Full Text] [Related]
30. Mineral metabolism in children with dermatomyositis.
Perez MD; Abrams SA; Koenning G; Stuff JE; O'Brien KO; Ellis KJ
J Rheumatol; 1994 Dec; 21(12):2364-9. PubMed ID: 7699644
[TBL] [Abstract][Full Text] [Related]
31. Decreased binding of insulin to its receptor in patients with congenital generalized lipodystrophy.
Oseid S; Beck-Nielsen H; Pedersen O; Sovik O
N Engl J Med; 1977 Feb; 296(5):245-8. PubMed ID: 831106
[TBL] [Abstract][Full Text] [Related]
32. [Lipoatrophic diabetes. Report of a case (author's transl)].
Zöllner N; Dörfler H; Wolfram G
MMW Munch Med Wochenschr; 1975 Jul; 117(29-30):1209-14. PubMed ID: 808720
[TBL] [Abstract][Full Text] [Related]
33. Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis.
Eimer MJ; Brickman WJ; Seshadri R; Ramsey-Goldman R; McPherson DD; Smulevitz B; Stone NJ; Pachman LM
J Pediatr; 2011 Nov; 159(5):795-801. PubMed ID: 21784434
[TBL] [Abstract][Full Text] [Related]
34. Partial lipodystrophy and insulin-resistant diabetes.
Crome P; Keen H
Diabete Metab; 1978 Jun; 4(2):81-4. PubMed ID: 680314
[TBL] [Abstract][Full Text] [Related]
35. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity.
Bingham A; Mamyrova G; Rother KI; Oral E; Cochran E; Premkumar A; Kleiner D; James-Newton L; Targoff IN; Pandey JP; Carrick DM; Sebring N; O'Hanlon TP; Ruiz-Hidalgo M; Turner M; Gordon LB; Laborda J; Bauer SR; Blackshear PJ; Imundo L; Miller FW; Rider LG;
Medicine (Baltimore); 2008 Mar; 87(2):70-86. PubMed ID: 18344805
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.
Ebihara K; Kusakabe T; Hirata M; Masuzaki H; Miyanaga F; Kobayashi N; Tanaka T; Chusho H; Miyazawa T; Hayashi T; Hosoda K; Ogawa Y; DePaoli AM; Fukushima M; Nakao K
J Clin Endocrinol Metab; 2007 Feb; 92(2):532-41. PubMed ID: 17118991
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry.
Bader-Meunier B; Decaluwe H; Barnerias C; Gherardi R; Quartier P; Faye A; Guigonis V; Pagnier A; Brochard K; Sibilia J; Gottenberg JE; Bodemer C;
J Rheumatol; 2011 Jul; 38(7):1436-40. PubMed ID: 21677003
[TBL] [Abstract][Full Text] [Related]
38. Lipodystrophy and metabolic abnormalities in a case of adult dermatomyositis.
Lee LA; Hobbs KF
J Am Acad Dermatol; 2007 Nov; 57(5 Suppl):S85-7. PubMed ID: 17938031
[TBL] [Abstract][Full Text] [Related]
39. [Successful insulin therapy in lipoatrophic diabetes].
Böhmer K; Hauner H; Phlippen R; Gries FA
Dtsch Med Wochenschr; 1991 Mar; 116(12):454-9. PubMed ID: 2004587
[TBL] [Abstract][Full Text] [Related]
40. Juvenile dermatomyositis: extramuscular manifestations and their management.
Lowry CA; Pilkington CA
Curr Opin Rheumatol; 2009 Nov; 21(6):575-80. PubMed ID: 19730375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
